Literature DB >> 17168995

A surveillance network for meningococcal disease in Europe.

Caroline L Trotter1, Manosree Chandra, Rosa Cano, Amparo Larrauri, Mary E Ramsay, Carina Brehony, Keith A Jolley, Martin C J Maiden, Sigrid Heuberger, Matthias Frosch.   

Abstract

Between 1999 and 2004, the European Union Invasive Bacterial Infections Surveillance Network (EU-IBIS) received c. 50,000 reports of meningococcal disease from 27 participating countries. Analysis has demonstrated a major decline in the incidence of invasive disease in those countries that have introduced routine vaccination against serogroup C infection. The establishment of rapid reporting of W135 and B2a/B2b strains has been able to provide early reassurance that these strains are not emerging as major public health problems in Europe. Between September 2001 and February 2005, the EU-MenNet project offered further opportunities for enhancing this data resource. Collaborative projects included: improving the EU-IBIS website; reviewing case ascertainment in Europe; reviewing cost-effectiveness studies for meningococcal serogroup C conjugate (MCC) vaccination; international comparisons of MCC vaccine efficacy; and mathematical modelling studies. In addition, linking of data from the European Meningococcal Multi-locus Sequence Type Centre to epidemiological data was performed. Particular clonal complexes were found to be preferentially associated with certain serogroups. Case fatality was also found to vary with clonal complex, suggesting that genotype can be a marker for hypervirulence. The importance of close collaboration between networks of epidemiologists, microbiologists, and the wider scientific and public health community is demonstrated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17168995     DOI: 10.1111/j.1574-6976.2006.00060.x

Source DB:  PubMed          Journal:  FEMS Microbiol Rev        ISSN: 0168-6445            Impact factor:   16.408


  55 in total

Review 1.  Biofilm formation by the human pathogen Neisseria meningitidis.

Authors:  Martin Lappann; Ulrich Vogel
Journal:  Med Microbiol Immunol       Date:  2010-04-08       Impact factor: 3.402

2.  Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.

Authors:  Ana Cristina C Frota; Lucimar G Milagres; Lee H Harrison; Bianca Ferreira; Daniela Menna Barreto; Gisele S Pereira; Aline C Cruz; Wania Pereira-Manfro; Ricardo Hugo de Oliveira; Thalita F Abreu; Cristina B Hofer
Journal:  Pediatr Infect Dis J       Date:  2015-05       Impact factor: 2.129

3.  Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates.

Authors:  Jeannette N Williams; Paul J Skipp; C David O'Connor; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

4.  Clonal analysis of Neisseria meningitidis serogroup B strains in South Africa, 2002 to 2006: emergence of new clone ST-4240/6688.

Authors:  Chivonne Moodley; Mignon du Plessis; Kedibone Ndlangisa; Linda de Gouveia; Keith P Klugman; Anne von Gottberg
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

5.  Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years.

Authors:  Roberto Gasparini; Maurizio Comanducci; Daniela Amicizia; Filippo Ansaldi; Paola Canepa; Andrea Orsi; Giancarlo Icardi; Emanuela Rizzitelli; Gabriella De Angelis; Stefania Bambini; Monica Moschioni; Sara Comandi; Isabella Simmini; Giueseppe Boccadifuoco; Brunella Brunelli; Marzia Monica Giuliani; Mariagrazia Pizza; Donatella Panatto
Journal:  J Clin Microbiol       Date:  2014-03-19       Impact factor: 5.948

6.  Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.

Authors:  Susanne P Stoof; Mariëtte B van Ravenhorst; Debbie M van Rooijen; Richarda M de Voer; Fiona R M van der Klis; Greet J Boland; Elisabeth A M Sanders; Guy A M Berbers; Peter F Teunis
Journal:  Clin Vaccine Immunol       Date:  2017-02-06

Review 7.  Review of meningococcal group B vaccines.

Authors:  Dan M Granoff
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

8.  Meningococcal disease: shifting epidemiology and genetic mechanisms that may contribute to serogroup C virulence.

Authors:  Jessica R Macneil; Jennifer D Thomas; Amanda C Cohn
Journal:  Curr Infect Dis Rep       Date:  2011-08       Impact factor: 3.725

Review 9.  Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

Authors:  Caroline L Trotter; Martin C J Maiden
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

10.  Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines.

Authors:  Joanne E Russell; Rachel Urwin; Stephen J Gray; Andrew J Fox; Ian M Feavers; Martin C J Maiden
Journal:  Microbiology (Reading)       Date:  2008-04       Impact factor: 2.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.